Entrada Therapeutics (TRDA) Shares Outstanding (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Shares Outstanding (Entity) of $38.8 million for Q1 2026, up 2.29% year-over-year from $38.0 million in Q1 2025, and up 1.4% quarter-over-quarter from $38.3 million in Q4 2025.
Entrada Therapeutics (TRDA) Shares Outstanding (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $38.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.29% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $38.8 million (up 2.29% YoY), while the FY2025 annual figure was $38.3 million, up 1.86% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $38.8 million, up from $38.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $38.8 million in Q1 2026, with the low at $31.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $33.6 million (2024), against an average of $35.0 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) soared 2358.97% in 2022, then climbed 1.35% in 2024.
- Entrada Therapeutics' Shares Outstanding (Entity) stood at $31.4 million in 2022, then climbed by 6.4% to $33.5 million in 2023, then increased by 12.33% to $37.6 million in 2024, then advanced by 1.86% to $38.3 million in 2025, then climbed by 1.4% to $38.8 million in 2026.
- Business Quant data shows TRDA's Shares Outstanding (Entity) at $38.8 million in Q1 2026, $38.3 million in Q4 2025, and $38.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 42.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.22 Mn |
| Mar 31, 2026 | 41.84 Mn |
| Dec 31, 2025 | 41.37 Mn |
| Sep 30, 2025 | 41.46 Mn |
| Jun 30, 2025 | 41.34 Mn |
| Mar 31, 2025 | 41.07 Mn |
| Dec 31, 2024 | 37.31 Mn |
| Sep 30, 2024 | 40.63 Mn |
| Jun 30, 2024 | 34.18 Mn |
| Mar 31, 2024 | 33.50 Mn |
| Dec 31, 2023 | 33.05 Mn |
| Sep 30, 2023 | 33.28 Mn |
| Jun 30, 2023 | 33.16 Mn |
| Mar 31, 2023 | 32.37 Mn |
| Dec 31, 2022 | 31.29 Mn |
| Sep 30, 2022 | 31.30 Mn |
| Jun 30, 2022 | 31.28 Mn |
| Mar 31, 2022 | 31.25 Mn |
| Dec 31, 2021 | 6.27 Mn |
| Sep 30, 2021 | 1.48 Mn |